riluzole has been researched along with Conus Medullaris Syndrome in 4 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Adverse events were analysed in the modified intention-to-treat (mITT) population, defined as all patients who underwent randomisation, including those who did not ultimately undergo surgical decompression." | 3.01 | Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. ( Ahn, H; Arnold, PM; Badhiwala, JH; Brodke, DS; Farhadi, HF; Fehlings, MG; Fourney, DR; Harrop, JS; Hilibrand, AS; Jacobs, WB; Kelly, M; Kim, KD; Kopjar, B; Massicotte, EM; Mummaneni, P; Nassr, A; Riew, KD; Santaguida, C; Shaffrey, CI; Vaccaro, AR; Wilson, J; Yoon, ST, 2021) |
| "Although paralysis was seen following trauma, seven of 10 animals receiving riluzole recovered motor function and nearly normal behaviour, unlike animals receiving vehicle." | 1.29 | The effect of riluzole on post-traumatic spinal cord injury in the rat. ( Boraud, T; Gross, C; Pratt, J; Stutzmann, JM, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moghaddamjou, A | 1 |
| Badhiwala, JH | 2 |
| Fehlings, MG | 3 |
| Ahn, H | 1 |
| Farhadi, HF | 1 |
| Shaffrey, CI | 1 |
| Nassr, A | 1 |
| Mummaneni, P | 1 |
| Arnold, PM | 1 |
| Jacobs, WB | 1 |
| Riew, KD | 1 |
| Kelly, M | 1 |
| Brodke, DS | 1 |
| Vaccaro, AR | 1 |
| Hilibrand, AS | 1 |
| Wilson, J | 1 |
| Harrop, JS | 1 |
| Yoon, ST | 1 |
| Kim, KD | 1 |
| Fourney, DR | 1 |
| Santaguida, C | 1 |
| Massicotte, EM | 1 |
| Kopjar, B | 1 |
| Stutzmann, JM | 1 |
| Pratt, J | 1 |
| Boraud, T | 1 |
| Gross, C | 1 |
| Schwartz, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Riluzole in Patients With Cervical Spondylotic Myelopathy Undergoing Surgical Treatment. A Randomized, Double-Blind, Placebo-controlled Multi-Center Study[NCT01257828] | Phase 3 | 270 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for riluzole and Conus Medullaris Syndrome
| Article | Year |
|---|---|
Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cervical Vertebrae; Combined Modality Therapy; Decompres | 2021 |
3 other studies available for riluzole and Conus Medullaris Syndrome
| Article | Year |
|---|---|
Degenerative Cervical Myelopathy: Changing Frontiers.
Topics: Cell- and Tissue-Based Therapy; Cervical Vertebrae; Excitatory Amino Acid Antagonists; Genetic Thera | 2020 |
The effect of riluzole on post-traumatic spinal cord injury in the rat.
Topics: Anesthesia; Animals; Evoked Potentials, Somatosensory; Hemorrhage; Male; Neuroprotective Agents; Par | 1996 |
Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole.
Topics: Animals; Axons; Behavior, Animal; Efferent Pathways; Female; Neuroprotective Agents; Rats; Rats, Wis | 2001 |